Literature DB >> 11071016

Antiviral and immunomodulatory effect of lithium.

J K Rybakowski1.   

Abstract

Experimental and clinical data pointing to antiviral and immunomodulatory effects of lithium have been reviewed in the context of new information accumulated in the last recent two decades, indicating a possible pathogenic role of viral infection and/or immune dysfunction in affective illness. Antiviral effects of lithium, particularly against herpes viruses, was demonstrated in both experimental and clinical conditions. Patients with affective illness taking lithium for prophylactic purposes have a greatly reduced frequency of labial herpes recurrences. The therapeutic action of oral and topical lithium administration on labial and genital herpes was also demonstrated in non-affective subjects. In both experimental conditions and in clinical studies with affective patients, lithium was shown to exert favorable effects on many parameters of cellular and humoral immunity. The evidence was also presented that lithium may alleviate the immune-endocrine component concomitant to an acute affective episode, such as acute phase reaction, cytokine secretion and hyperactivation of hypothalamic-pituitary-adrenal axis. It is speculated that the antiviral and immunomodulatory properties of lithium may contribute to psychotropic actions of this ionic drug, especially prevention of recurrences in affective illness.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11071016

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  12 in total

1.  Psychiatric aspects of toxoplasmosis: an Indian perspective.

Authors:  Ajish G Mangot
Journal:  J Parasit Dis       Date:  2015-05-15

2.  Deregulation of Tpl2 and NF-kappaB signaling and induction of macrophage apoptosis by the anti-depressant drug lithium.

Authors:  Minying Zhang; Wei Jin; Xiaofei Zhou; Jiayi Yu; Andrew J Lee; Shao-Cong Sun
Journal:  Cell Signal       Date:  2008-12-25       Impact factor: 4.315

3.  Lithium inhibits growth of intracellular Mycobacterium kansasii through enhancement of macrophage apoptosis.

Authors:  Hosung Sohn; Kwangwook Kim; Kil-Soo Lee; Han-Gyu Choi; Kang-In Lee; A-Rum Shin; Jong-Seok Kim; Sung Jae Shin; Chang-Hwa Song; Jeong-Kyu Park; Hwa-Jung Kim
Journal:  J Microbiol       Date:  2014-02-17       Impact factor: 3.422

4.  Utilization of never-medicated bipolar disorder patients towards development and validation of a peripheral biomarker profile.

Authors:  Catherine L Clelland; Laura L Read; Laura J Panek; Robert H Nadrich; Carter Bancroft; James D Clelland
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

5.  Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia.

Authors:  P Brambilla; M Bellani; M Isola; A Bergami; V Marinelli; N Dusi; G Rambaldelli; M Tansella; A Maria Finardi; G Martino; C Perlini; R Furlan
Journal:  Transl Psychiatry       Date:  2014-07-01       Impact factor: 6.222

Review 6.  Assessing brain immune activation in psychiatric disorders: clinical and preclinical PET imaging studies of the 18-kDa translocator protein.

Authors:  Thalia F van der Doef; Janine Doorduin; Bart N M van Berckel; Simon Cervenka
Journal:  Clin Transl Imaging       Date:  2015-09-10

7.  Lithium Salts of Krebs Cycle Substrates as Potential Normothymic Antioxidant Agents.

Authors:  Evgenii Plotnikov; Elena Korotkova; Olesya Voronova
Journal:  J Pharm Bioallied Sci       Date:  2018 Oct-Dec

8.  Lithium as a candidate treatment for COVID-19: Promises and pitfalls.

Authors:  Ravi Philip Rajkumar
Journal:  Drug Dev Res       Date:  2020-06-10       Impact factor: 4.360

9.  Inflammatory monocyte gene expression: trait or state marker in bipolar disorder?

Authors:  K Becking; B C M Haarman; R F Riemersma van der Lek; L Grosse; W A Nolen; S Claes; H A Drexhage; R A Schoevers
Journal:  Int J Bipolar Disord       Date:  2015-09-17

Review 10.  Challenging the Negative Perception of Lithium and Optimizing Its Long-Term Administration.

Authors:  Janusz K Rybakowski
Journal:  Front Mol Neurosci       Date:  2018-10-02       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.